- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03164980
Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer (COMPASS)
Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer
This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer.
The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD with other standard platinum-based chemotherapy in platinum-sensitive disease.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer.
The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD with other standard platinum-based chemotherapy in platinum-sensitive disease.
Patients with recurrent, platinum-sensitive, ovarian, fallopian tube and peritoneal cancer will be stratified according to surgery for relapse (R0 vs. R1/2 resection) vs. no surgery in the same setting and age (< 75 years vs. ≥ 75 years), and randomized 1:1 to receive either trabectedin/PLD (Arm A) or one of 3 platinum-based standard therapies without bevacizumab (Arm B, "other standard therapy"). In case of randomization to "other standard therapy", the investigator has the choice between carboplatin/PLD, carboplatin/gemcitabine and carboplatin/paclitaxel. Patients in both treatment arms will receive chemotherapy up for 6 cycles or until disease progression (PD), unacceptable toxicities or patient's wish to stop therapy, whichever occurs first.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Annika Stürzebecher, Dr.
- Phone Number: +49 30 403 68 65 41
- Email: annika.stuerzebecher@noggo.de
Study Contact Backup
- Name: Maren Keller, Dr.
- Phone Number: +49 30 403 68 65 32
- Email: maren.keller@noggo.de
Study Locations
-
-
-
Aachen, Germany, 52074
- Universitätsklinikum Aachen
-
Berlin, Germany, 13353
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
-
Berlin, Germany, 10713
- Sankt Gertrauden-Krankenhaus
-
Berlin, Germany, 13597
- Praxis Krebsheilkunde für Frauen
-
Bonn, Germany, 53111
- Medizinisches Zentrum Bonn Friedensplatz
-
Brandenburg an der Havel, Germany, 14770
- Universitätsklinikum Brandenburg an der Havel
-
Braunschweig, Germany, 38100
- Studien GbR Braunschweig
-
Dessau-Roßlau, Germany, 06847
- Städtisches Klinikum Dessau
-
Dresden, Germany, 01307
- Onkologische Schwerpunktpraxis
-
Dresden, Germany, 01307
- Frauenklinik Carl Gustav Carus
-
Frankfurt, Germany, 60488
- Krankenhaus Nordwest gGmbH
-
Freiburg, Germany, 79106
- Universitätsklinikum Freiburg
-
Krefeld, Germany, 47805
- ZAGO am Helios Klinikum Krefeld
-
Leipzig, Germany, 04103
- Universitätsfrauenklinik Leipzig
-
Mainz, Germany, 55131
- Universitätsklinik der Johannes Gutenberg-Universität Mainz
-
Neuruppin, Germany, 16816
- Ruppiner Kliniken GmbH
-
Offenbach, Germany, 63069
- Sana Klinikum Offenbach
-
Rostock, Germany, 18059
- Klinikum Südstadt Rostock
-
Saarbrücken, Germany, 66113
- Caritas Klinikum St. Theresia
-
Saarlouis, Germany, 66740
- Krankenhaus Saarlouis vom DRK
-
Unna, Germany, 59423
- Christliches Klinikum Unna gGmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- Women aged ≥ 18 years
- Patients with histologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube cancer who received ≥1 prior chemotherapy
- Patients must be eligible for platin-containing therapy; Patient is defined as platin-sensitive when considered for platin-containing therapy by the investigator. The time frame from end of prior therapy until disease progression alone is not pivotal for study participation. Patients without a platin-containing regimen in the previous line who are also eligible for platin-containing regime are also appropriate for participation
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
Adequate baseline organ function as defined as
- Leucocytes > 3.0 x 109/l
- Platelet count > 100 x 109/l
- Absolute neutrophil count (ANC) ≥1500/mm3
- Haemoglobin ≥ 9 g/dl
- Alkaline Phosphatase (AP) ≤ 2.5 × ULN (consider hepatic isoenzymes 5 nucleotidase or gamma glutamyl transpeptidase (GGT), if the elevation could be osseous in origin)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
- Creatinine-Clearance ≥ 60 ml/min (MDRD formula or Cockroft & Gault formula)
- Serum creatinine ≤ 1.5 mg/dl
- Creatine phosphokinase (CPK) ≤ 2.5 × ULN
- Total bilirubin < ULN
- Women of childbearing potential should use contraceptives or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication or be surgically sterile.
- Adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥ 50% as determined by echocardiogram
- Patients must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures.
Exclusion criteria
- Only malignancies, which influence the prognosis
- Any unstable or serious concurrent condition (e.g. active infection requiring systemic therapy).
- Chemotherapy or radiation therapy or tumor embolization within 2 weeks prior to the first dose of study drug or planned during study participation.
- Patients who have refractory disease. Refractory disease is defined if relapse occurs <4 months after beginning of platin-containing therapy.
- Hypersensitivity to the active substance or to any of the excipients of study drug
- Findings from ECG and/or assessment of LVEF which indicate an anthracycline-related cardiotoxic process which contradicts administration of liposomal doxorubicin in accordance with the requirements of the SmPC of PLD.
- Biological therapy, immunotherapy, hormonal therapy or treatment with an investigational agent within 14 days (for bevacizumab, 30 days) prior to the first dose of study drug.
- Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- Participation in another clinical study with experimental therapy within the 30 days before start of and during treatment. Participation in a non-interventional study should be discussed with sponsor and NC beforehand.
- Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4)
- Patients who are depending on the sponsor/CRO or investigational site as well as on the investigator.
- Pregnancy or lactation period, or planning to become pregnant within 7 months after the end of treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
PLD followed by Trabectedin.
Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
|
To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
|
Experimental: Arm B
|
To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
observation of change in QoL
Time Frame: 3 month
|
QoL change from baseline (C1 D1) to after 3 months (± 2 week) or at progression, whichever occurs first.
(EORTC QLQ-C30 in combination with EORTC QLQ-ov28)
|
3 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in QoL
Time Frame: 12 month
|
measured at day one of every treatment cycle, at the end of the treatment and after 6 and 12 month (follow up) (EORTC QLQ-C30 in combination with EORTC QLQ-ov28).
|
12 month
|
Progression-free survival
Time Frame: 18 month
|
18 month
|
|
Overall survival
Time Frame: 18 month
|
18 month
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jalid Sehouli, Prof., Charite University, Berlin, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Disease Attributes
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Hypersensitivity
- Recurrence
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Trabectedin
Other Study ID Numbers
- NOGGO S16/COMPASS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaRecruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on Trabectidin (Yondelis)
-
Italian Sarcoma GroupCompleted
-
University of Texas Southwestern Medical CenterJohnson & Johnson Pharmaceutical Research & Development, L.L.C.No longer availableSoft Tissue SarcomaUnited States
-
PharmaMar, SpainCompletedSoft Tissue SarcomaGermany
-
Italian Sarcoma GroupCompletedMetastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive | Standard ChemotherapyItaly
-
Universität MünsterAnturec Pharmaceuticals GmbHRecruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedCarcinosarcoma, Ovarian | Carcinosarcomas UterineItaly
-
European Organisation for Research and Treatment...PharmaMarTerminatedSarcoma, Soft TissueFrance, Germany, Spain, Netherlands, Poland, United Kingdom
-
Catholic University of the Sacred HeartUnknownBRCA1 and BRCA2 Mutation Carrier and BRCAness PhenotypeItaly
-
ARCAGY/ GINECO GROUPPharmaMarCompletedOvarian CancerFrance
-
Grupo Espanol de Investigacion en SarcomasCentre Leon Berard; Italian Sarcoma GroupRecruitingSarcoma, Soft Tissue | Leiomyosarcoma | Liposarcoma | Liposarcoma, Myxoid | Pleomorphic LiposarcomaFrance, Spain, Italy